Treatments for erectile dysfunction in spinal cord patients: alternatives to phosphodiesterase type 5 inhibitors? A review study
Study design: Review study. Objectives: Alternative treatments to oral phosphodiesterase type 5 inhibitors (PDE5Is) in individuals with spinal cord lesions (SCLs) and erectile dysfunction (ED). Setting: Italy. Methods: Research clinical trials (1999–2014). Results: Twelve studies were selected. One...
Gespeichert in:
| Veröffentlicht in: | Spinal cord 2015-12, Vol.53 (12), p.849-854 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 854 |
|---|---|
| container_issue | 12 |
| container_start_page | 849 |
| container_title | Spinal cord |
| container_volume | 53 |
| creator | Lombardi, G Musco, S Wyndaele, J J Del Popolo, G |
| description | Study design:
Review study.
Objectives:
Alternative treatments to oral phosphodiesterase type 5 inhibitors (PDE5Is) in individuals with spinal cord lesions (SCLs) and erectile dysfunction (ED).
Setting:
Italy.
Methods:
Research clinical trials (1999–2014).
Results:
Twelve studies were selected. One article documented that 76% of subjects reached satisfactory sexual intercourse (SI) using intracavernosal injection of vasoactive medications (papaverine and prostaglandin E1). One study regarding perineal training showed a significant increase (
P |
| doi_str_mv | 10.1038/sc.2015.116 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1765983286</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1765983286</sourcerecordid><originalsourceid>FETCH-LOGICAL-c494t-2de8abecad7fe57ec13893d1d6f0e13f7642f050fa13b9e658b398214974c2b13</originalsourceid><addsrcrecordid>eNqNkU1rFTEUhoMotlZX7iXgRtC55msyiRspxS8ouKnrIZOcsSlzJ2NOpnJ3_nQz3CoiLlyEnHCePCfkJeQpZzvOpHmNficYb3ec63vklKtON60W6n6tpRaNklaekEeIN4wxy615SE6E5lYazk_Jj6sMruxhLkjHlClk8CVOQMMBx3WudZppnCkucXYT9SkHurgStwtvqJsK5LkebwFpSXS5TlhXiIC14RBoOSxA22q4jkMsKeNbek4z3Eb4TrGs4fCYPBjdhPDkbj8jX96_u7r42Fx-_vDp4vyy8cqq0ogAxg3gXehGaDvwXBorAw96ZMDl2GklRtay0XE5WNCtGaQ1givbKS8GLs_Ii6N3yenbWt_X7yN6mCY3Q1qx551urZHC6P9AldKatR2r6PO_0Ju01h-ZNkpaZrW1m_DlkfI5IWYY-yXHvcuHnrN-y7BH328Z9jXDSj-7c67DHsJv9ldoFXh1BLC25q-Q_xj6D99PbVGnGw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1739096996</pqid></control><display><type>article</type><title>Treatments for erectile dysfunction in spinal cord patients: alternatives to phosphodiesterase type 5 inhibitors? A review study</title><source>MEDLINE</source><source>SpringerLink Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Lombardi, G ; Musco, S ; Wyndaele, J J ; Del Popolo, G</creator><creatorcontrib>Lombardi, G ; Musco, S ; Wyndaele, J J ; Del Popolo, G</creatorcontrib><description>Study design:
Review study.
Objectives:
Alternative treatments to oral phosphodiesterase type 5 inhibitors (PDE5Is) in individuals with spinal cord lesions (SCLs) and erectile dysfunction (ED).
Setting:
Italy.
Methods:
Research clinical trials (1999–2014).
Results:
Twelve studies were selected. One article documented that 76% of subjects reached satisfactory sexual intercourse (SI) using intracavernosal injection of vasoactive medications (papaverine and prostaglandin E1). One study regarding perineal training showed a significant increase (
P
<0.05) in penile tumescence in 10 individuals with preserved sacral segment. Two studies reported contrasting results on erectile function (EF) using various dosages of oral fampridine (25–40 mg). Furthermore, 95.1% of patients on fampridine 25 mg experienced drawbacks. Disappointing findings were found with intraurethral alprostadil (125–1000 μg) and sublingual apomorphine 3 mg. Two studies concerning penile prosthesis reported valid SI more than 75% of the time with a mean follow-up of 11 years, although around 15% of individuals showed side effects. As for surgical treatments, 88% of males submitted to Brindley sacral anterior root stimulator after sacral dorsal rhizotomy achieved valid erection up to 8 years following the procedure. Three studies documented the impact of definitive sacral neuromodulation implant (Medtronic, Minneapolis, MN, USA) also on EF. After surgery, 20–37.5% of patients with ED recovered normal EF.
Conclusions:
Data are scant on the efficacy of ED treatments for SCL subjects who did not respond to PDE5Is. Further research should investigate the effects of any SCL treatments even when they are not strictly used for neurogenic sexual dysfunction.</description><identifier>ISSN: 1362-4393</identifier><identifier>EISSN: 1476-5624</identifier><identifier>DOI: 10.1038/sc.2015.116</identifier><identifier>PMID: 26193811</identifier><identifier>CODEN: SPCOFM</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>4-Aminopyridine - therapeutic use ; 692/699/2768/1575 ; 692/699/2768/515 ; Anatomy ; Biomedical and Life Sciences ; Biomedicine ; Clinical Trials as Topic - statistics & numerical data ; Dose-Response Relationship, Drug ; Erectile Dysfunction - drug therapy ; Erectile Dysfunction - etiology ; Human Physiology ; Humans ; Longitudinal Studies ; Male ; MEDLINE - statistics & numerical data ; Neurochemistry ; Neuropsychology ; Neurosciences ; Phosphodiesterase 5 Inhibitors - therapeutic use ; review ; Spinal Cord Injuries - complications ; Spinal Cord Injuries - drug therapy ; Spinal Cord Injuries - surgery</subject><ispartof>Spinal cord, 2015-12, Vol.53 (12), p.849-854</ispartof><rights>International Spinal Cord Society 2015</rights><rights>Copyright Nature Publishing Group Dec 2015</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c494t-2de8abecad7fe57ec13893d1d6f0e13f7642f050fa13b9e658b398214974c2b13</citedby><cites>FETCH-LOGICAL-c494t-2de8abecad7fe57ec13893d1d6f0e13f7642f050fa13b9e658b398214974c2b13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/sc.2015.116$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1038/sc.2015.116$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26193811$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lombardi, G</creatorcontrib><creatorcontrib>Musco, S</creatorcontrib><creatorcontrib>Wyndaele, J J</creatorcontrib><creatorcontrib>Del Popolo, G</creatorcontrib><title>Treatments for erectile dysfunction in spinal cord patients: alternatives to phosphodiesterase type 5 inhibitors? A review study</title><title>Spinal cord</title><addtitle>Spinal Cord</addtitle><addtitle>Spinal Cord</addtitle><description>Study design:
Review study.
Objectives:
Alternative treatments to oral phosphodiesterase type 5 inhibitors (PDE5Is) in individuals with spinal cord lesions (SCLs) and erectile dysfunction (ED).
Setting:
Italy.
Methods:
Research clinical trials (1999–2014).
Results:
Twelve studies were selected. One article documented that 76% of subjects reached satisfactory sexual intercourse (SI) using intracavernosal injection of vasoactive medications (papaverine and prostaglandin E1). One study regarding perineal training showed a significant increase (
P
<0.05) in penile tumescence in 10 individuals with preserved sacral segment. Two studies reported contrasting results on erectile function (EF) using various dosages of oral fampridine (25–40 mg). Furthermore, 95.1% of patients on fampridine 25 mg experienced drawbacks. Disappointing findings were found with intraurethral alprostadil (125–1000 μg) and sublingual apomorphine 3 mg. Two studies concerning penile prosthesis reported valid SI more than 75% of the time with a mean follow-up of 11 years, although around 15% of individuals showed side effects. As for surgical treatments, 88% of males submitted to Brindley sacral anterior root stimulator after sacral dorsal rhizotomy achieved valid erection up to 8 years following the procedure. Three studies documented the impact of definitive sacral neuromodulation implant (Medtronic, Minneapolis, MN, USA) also on EF. After surgery, 20–37.5% of patients with ED recovered normal EF.
Conclusions:
Data are scant on the efficacy of ED treatments for SCL subjects who did not respond to PDE5Is. Further research should investigate the effects of any SCL treatments even when they are not strictly used for neurogenic sexual dysfunction.</description><subject>4-Aminopyridine - therapeutic use</subject><subject>692/699/2768/1575</subject><subject>692/699/2768/515</subject><subject>Anatomy</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Clinical Trials as Topic - statistics & numerical data</subject><subject>Dose-Response Relationship, Drug</subject><subject>Erectile Dysfunction - drug therapy</subject><subject>Erectile Dysfunction - etiology</subject><subject>Human Physiology</subject><subject>Humans</subject><subject>Longitudinal Studies</subject><subject>Male</subject><subject>MEDLINE - statistics & numerical data</subject><subject>Neurochemistry</subject><subject>Neuropsychology</subject><subject>Neurosciences</subject><subject>Phosphodiesterase 5 Inhibitors - therapeutic use</subject><subject>review</subject><subject>Spinal Cord Injuries - complications</subject><subject>Spinal Cord Injuries - drug therapy</subject><subject>Spinal Cord Injuries - surgery</subject><issn>1362-4393</issn><issn>1476-5624</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNqNkU1rFTEUhoMotlZX7iXgRtC55msyiRspxS8ouKnrIZOcsSlzJ2NOpnJ3_nQz3CoiLlyEnHCePCfkJeQpZzvOpHmNficYb3ec63vklKtON60W6n6tpRaNklaekEeIN4wxy615SE6E5lYazk_Jj6sMruxhLkjHlClk8CVOQMMBx3WudZppnCkucXYT9SkHurgStwtvqJsK5LkebwFpSXS5TlhXiIC14RBoOSxA22q4jkMsKeNbek4z3Eb4TrGs4fCYPBjdhPDkbj8jX96_u7r42Fx-_vDp4vyy8cqq0ogAxg3gXehGaDvwXBorAw96ZMDl2GklRtay0XE5WNCtGaQ1givbKS8GLs_Ii6N3yenbWt_X7yN6mCY3Q1qx551urZHC6P9AldKatR2r6PO_0Ju01h-ZNkpaZrW1m_DlkfI5IWYY-yXHvcuHnrN-y7BH328Z9jXDSj-7c67DHsJv9ldoFXh1BLC25q-Q_xj6D99PbVGnGw</recordid><startdate>20151201</startdate><enddate>20151201</enddate><creator>Lombardi, G</creator><creator>Musco, S</creator><creator>Wyndaele, J J</creator><creator>Del Popolo, G</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T7</scope><scope>7TK</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PJZUB</scope><scope>PKEHL</scope><scope>PPXIY</scope><scope>PQEST</scope><scope>PQGLB</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20151201</creationdate><title>Treatments for erectile dysfunction in spinal cord patients: alternatives to phosphodiesterase type 5 inhibitors? A review study</title><author>Lombardi, G ; Musco, S ; Wyndaele, J J ; Del Popolo, G</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c494t-2de8abecad7fe57ec13893d1d6f0e13f7642f050fa13b9e658b398214974c2b13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>4-Aminopyridine - therapeutic use</topic><topic>692/699/2768/1575</topic><topic>692/699/2768/515</topic><topic>Anatomy</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Clinical Trials as Topic - statistics & numerical data</topic><topic>Dose-Response Relationship, Drug</topic><topic>Erectile Dysfunction - drug therapy</topic><topic>Erectile Dysfunction - etiology</topic><topic>Human Physiology</topic><topic>Humans</topic><topic>Longitudinal Studies</topic><topic>Male</topic><topic>MEDLINE - statistics & numerical data</topic><topic>Neurochemistry</topic><topic>Neuropsychology</topic><topic>Neurosciences</topic><topic>Phosphodiesterase 5 Inhibitors - therapeutic use</topic><topic>review</topic><topic>Spinal Cord Injuries - complications</topic><topic>Spinal Cord Injuries - drug therapy</topic><topic>Spinal Cord Injuries - surgery</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lombardi, G</creatorcontrib><creatorcontrib>Musco, S</creatorcontrib><creatorcontrib>Wyndaele, J J</creatorcontrib><creatorcontrib>Del Popolo, G</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>ProQuest Health & Medical Research Collection</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Health & Nursing</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Applied & Life Sciences</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Spinal cord</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lombardi, G</au><au>Musco, S</au><au>Wyndaele, J J</au><au>Del Popolo, G</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatments for erectile dysfunction in spinal cord patients: alternatives to phosphodiesterase type 5 inhibitors? A review study</atitle><jtitle>Spinal cord</jtitle><stitle>Spinal Cord</stitle><addtitle>Spinal Cord</addtitle><date>2015-12-01</date><risdate>2015</risdate><volume>53</volume><issue>12</issue><spage>849</spage><epage>854</epage><pages>849-854</pages><issn>1362-4393</issn><eissn>1476-5624</eissn><coden>SPCOFM</coden><abstract>Study design:
Review study.
Objectives:
Alternative treatments to oral phosphodiesterase type 5 inhibitors (PDE5Is) in individuals with spinal cord lesions (SCLs) and erectile dysfunction (ED).
Setting:
Italy.
Methods:
Research clinical trials (1999–2014).
Results:
Twelve studies were selected. One article documented that 76% of subjects reached satisfactory sexual intercourse (SI) using intracavernosal injection of vasoactive medications (papaverine and prostaglandin E1). One study regarding perineal training showed a significant increase (
P
<0.05) in penile tumescence in 10 individuals with preserved sacral segment. Two studies reported contrasting results on erectile function (EF) using various dosages of oral fampridine (25–40 mg). Furthermore, 95.1% of patients on fampridine 25 mg experienced drawbacks. Disappointing findings were found with intraurethral alprostadil (125–1000 μg) and sublingual apomorphine 3 mg. Two studies concerning penile prosthesis reported valid SI more than 75% of the time with a mean follow-up of 11 years, although around 15% of individuals showed side effects. As for surgical treatments, 88% of males submitted to Brindley sacral anterior root stimulator after sacral dorsal rhizotomy achieved valid erection up to 8 years following the procedure. Three studies documented the impact of definitive sacral neuromodulation implant (Medtronic, Minneapolis, MN, USA) also on EF. After surgery, 20–37.5% of patients with ED recovered normal EF.
Conclusions:
Data are scant on the efficacy of ED treatments for SCL subjects who did not respond to PDE5Is. Further research should investigate the effects of any SCL treatments even when they are not strictly used for neurogenic sexual dysfunction.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>26193811</pmid><doi>10.1038/sc.2015.116</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1362-4393 |
| ispartof | Spinal cord, 2015-12, Vol.53 (12), p.849-854 |
| issn | 1362-4393 1476-5624 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1765983286 |
| source | MEDLINE; SpringerLink Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | 4-Aminopyridine - therapeutic use 692/699/2768/1575 692/699/2768/515 Anatomy Biomedical and Life Sciences Biomedicine Clinical Trials as Topic - statistics & numerical data Dose-Response Relationship, Drug Erectile Dysfunction - drug therapy Erectile Dysfunction - etiology Human Physiology Humans Longitudinal Studies Male MEDLINE - statistics & numerical data Neurochemistry Neuropsychology Neurosciences Phosphodiesterase 5 Inhibitors - therapeutic use review Spinal Cord Injuries - complications Spinal Cord Injuries - drug therapy Spinal Cord Injuries - surgery |
| title | Treatments for erectile dysfunction in spinal cord patients: alternatives to phosphodiesterase type 5 inhibitors? A review study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T15%3A13%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatments%20for%20erectile%20dysfunction%20in%20spinal%20cord%20patients:%20alternatives%20to%20phosphodiesterase%20type%205%20inhibitors?%20A%20review%20study&rft.jtitle=Spinal%20cord&rft.au=Lombardi,%20G&rft.date=2015-12-01&rft.volume=53&rft.issue=12&rft.spage=849&rft.epage=854&rft.pages=849-854&rft.issn=1362-4393&rft.eissn=1476-5624&rft.coden=SPCOFM&rft_id=info:doi/10.1038/sc.2015.116&rft_dat=%3Cproquest_cross%3E1765983286%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1739096996&rft_id=info:pmid/26193811&rfr_iscdi=true |